Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 4661-4670 Newer>

The Motley Fool December 1, 2004 Rick Aristotle Munarriz	No Mas, Wendy's The burger chain will be closing down 18 of its Baja Fresh eateries. Because of Baja's blunders, fourth-quarter results for Wendy's will show a loss of at least $1.02 a share.
The Motley Fool November 30, 2004 Dave Marino-Nachison	Business Models Gone Bad With narrowing losses, some cash on hand, and little debt, Franklin Covey might make it -- though with a market value around $36 million and a share price below $2.00, it's not for investors who aren't well-schooled in the ins and outs of small-company investing.
The Motley Fool November 30, 2004 Tim Beyers	Lockheed's Loss in Space Intelsat loses a satellite, which could mean lost millions for the defense contractor. Being a diversified company, Lockheed bet a very small amount of its economic well-being on the success of Intelsat. Should your portfolio be any different
The Motley Fool November 30, 2004 Tim Beyers	How to Profit From Wall Street's Wallflowers The efficient market theory doesn't apply to stocks that Wall Street and the media ignore. So the next time you're looking to invest, try one of Wall Street's ugly ducklings. You might just find one of the stock market's lucrative swans.
The Motley Fool November 30, 2004 Tim Beyers	Ripe Rule Breaker? Apple's stock has gone too far, too fast, and now it appears poised for an awfully messy fall.
The Motley Fool November 30, 2004 Jeff Hwang	Wynn-ing Ugly Even if Wynn Resorts isn't overvalued, how much can an investor expect to gain?
The Motley Fool November 30, 2004 W.D. Crotty	Ultimate Electronics' Shaky Base The specialty retailer's stock has soared thanks to a homebuilder's free plasma TV promotional, but not enough profits are built into the price.
The Motley Fool November 30, 2004 Seth Jayson	Priceline out of the Cold Priceline and Northwest Airlines split for good, and the Street yawns.
The Motley Fool November 30, 2004 Brian Gorman	Glaxo Targeted for Kids' Trials Criticism of Glaxo could benefit investors in the long run: Although these companies will continue to evolve, their role as dominant players in drug development seems secure. Those investors willing to dip a toe in now could reap rich rewards.
The Motley Fool November 30, 2004 W.D. Crotty	Earnings Pig-Out Near-record hog prices benefit Smithfield results. Net income for the latest quarter rose 61% from year-ago levels on a 32% gain in sales.
<Older 4661-4670 Newer> Return to current articles.